These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 14241882)

  • 41. Cost-effectiveness of oral cholera vaccine in a stable refugee population at risk for epidemic cholera and in a population with endemic cholera.
    Murray J; McFarland DA; Waldman RJ
    Bull World Health Organ; 1998; 76(4):343-52. PubMed ID: 9803585
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study.
    Khatib AM; Ali M; von Seidlein L; Kim DR; Hashim R; Reyburn R; Ley B; Thriemer K; Enwere G; Hutubessy R; Aguado MT; Kieny MP; Lopez AL; Wierzba TF; Ali SM; Saleh AA; Mukhopadhyay AK; Clemens J; Jiddawi MS; Deen J
    Lancet Infect Dis; 2012 Nov; 12(11):837-44. PubMed ID: 22954655
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vaccine Protection of Bangladeshi infants and young children against cholera: implications for vaccine deployment and person-to-person transmission.
    Ali M; Emch M; Yunus M; Sack D; Lopez AL; Holmgren J; Clemens J
    Pediatr Infect Dis J; 2008 Jan; 27(1):33-7. PubMed ID: 18162935
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evidence that inactivated oral cholera vaccines both prevent and mitigate Vibrio cholerae O1 infections in a cholera-endemic area.
    Clemens JD; Sack DA; Rao MR; Chakraborty J; Khan MR; Kay B; Ahmed F; Banik AK; van Loon FP; Yunus M
    J Infect Dis; 1992 Nov; 166(5):1029-34. PubMed ID: 1402014
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Estimation of vaccine efficacy in the presence of waning: application to cholera vaccines.
    Durham LK; Longini IM; Halloran ME; Clemens JD; Nizam A; Rao M
    Am J Epidemiol; 1998 May; 147(10):948-59. PubMed ID: 9596473
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serological studies in cholera. 3. Serum toxin neutralization--rise in titre in response to infection with Vibrio cholerae, and the level in the "normal" population of East Pakistan.
    Benenson AS; Saad A; Mosley WH; Ahmed A
    Bull World Health Organ; 1968; 38(2):287-95. PubMed ID: 5302304
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis.
    Jeuland M; Cook J; Poulos C; Clemens J; Whittington D;
    Value Health; 2009 Sep; 12(6):899-908. PubMed ID: 19824189
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness of an oral cholera vaccine campaign to prevent clinically-significant cholera in Odisha State, India.
    Wierzba TF; Kar SK; Mogasale VV; Kerketta AS; You YA; Baral P; Khuntia HK; Ali M; Kim YH; Rath SB; Bhattachan A; Sah B
    Vaccine; 2015 May; 33(21):2463-9. PubMed ID: 25850019
    [TBL] [Abstract][Full Text] [Related]  

  • 49. THE 1961 CHOLERA EPIDEMIC IN MANILA, REPUBLIC OF THE PHILIPPINES.
    WALLACE CK; FABIE AE; MANGUBAT O; VELASCO E; JUINIO C; PHILLIPS RA
    Bull World Health Organ; 1964; 30(6):795-810. PubMed ID: 14215186
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impaired immune response to natural infection as a correlate of vaccine failure in a field trial of killed oral cholera vaccines.
    Clemens J; Rao M; Sack D; Ahmed F; Khan MR; Chakraborty J; Kay B; Huda S; Yunus M; van Loon F
    Am J Epidemiol; 1995 Oct; 142(7):759-64. PubMed ID: 7572947
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A cost-benefit analysis of programmatic use of CVD 103-HgR live oral cholera vaccine in a high-risk population.
    Cookson ST; Stamboulian D; Demonte J; Quero L; Martinez de Arquiza C; Aleman A; Lepetic A; Levine MM
    Int J Epidemiol; 1997 Feb; 26(1):212-9. PubMed ID: 9126522
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An assessment of the value of cholera vaccine as used in a single dose mass inoculation; a field observation.
    KANT L
    J Trop Med Hyg; 1951 Nov; 54(11):223-5. PubMed ID: 14889594
    [No Abstract]   [Full Text] [Related]  

  • 53. Cholera today: bedside evaluation and treatment.
    Med Times; 1966 Sep; 94(9):1068-75. PubMed ID: 5946470
    [No Abstract]   [Full Text] [Related]  

  • 54. Cholera cases cluster in time and space in Matlab, Bangladesh: implications for targeted preventive interventions.
    Debes AK; Ali M; Azman AS; Yunus M; Sack DA
    Int J Epidemiol; 2016 Dec; 45(6):2134-2139. PubMed ID: 27789673
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mass vaccination with a two-dose oral cholera vaccine in a long-standing refugee camp, Thailand.
    Phares CR; Date K; Travers P; Déglise C; Wongjindanon N; Ortega L; Bhuket PR
    Vaccine; 2016 Jan; 34(1):128-33. PubMed ID: 26549363
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Coverage and acceptability of cholera vaccine among high-risk population of urban Dhaka, Bangladesh.
    Uddin MJ; Wahed T; Saha NC; Kaukab SS; Khan IA; Khan AI; Saha A; Chowdhury F; Clemens JD; Qadri F
    Vaccine; 2014 Sep; 32(43):5690-5. PubMed ID: 25149429
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Breast feeding and the risk of severe cholera in rural Bangladeshi children.
    Clemens JD; Sack DA; Harris JR; Khan MR; Chakraborty J; Chowdhury S; Rao MR; van Loon FP; Stanton BF; Yunus M
    Am J Epidemiol; 1990 Mar; 131(3):400-11. PubMed ID: 2301350
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of a bivalent killed whole-cell cholera vaccine over five years: a re-analysis of a cluster-randomized trial.
    Fong Y; Halloran ME; Park JK; Marks F; Clemens JD; Chao DL
    BMC Infect Dis; 2018 Feb; 18(1):84. PubMed ID: 29463233
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cholera and typhoid vaccine. The current state of play.
    Cohen J
    Aust Fam Physician; 1997 Aug; 26(8):943-6. PubMed ID: 9267060
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of oral cholera vaccines in cholera-endemic countries: A mathematical modeling study.
    Kim JH; Mogasale V; Burgess C; Wierzba TF
    Vaccine; 2016 Apr; 34(18):2113-20. PubMed ID: 26993337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.